Research programme: advanced stem cell therapies - Ferrer Advanced Biotherapeutics /Histocell

Drug Profile

Research programme: advanced stem cell therapies - Ferrer Advanced Biotherapeutics /Histocell

Alternative Names: HC 016; Tissue engineering drugs - Ferrer/Histocell

Latest Information Update: 25 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferrer; Histocell
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain injuries; Cartilage disorders

Most Recent Events

  • 18 Feb 2014 Ferrer and Histocell agree to co-develop Advanced stem cell therapy in Spain for Cartilage disorders, brain and spinal cord injuries
  • 18 Feb 2014 Preclinical trials in Brain injuries in Spain (unspecified route)
  • 18 Feb 2014 Preclinical trials in Cartilage disorders in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top